Auxiliary pharmaceutical composition for chemoradiotherapy of newly-diagnosed glioblastoma
A technology for glioblastoma and composition, applied in the field of biomedicine, can solve the problem of unclear mechanism of action, and achieve the effect of significant therapeutic effect and good application prospect.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0014] An adjuvant drug composition for newly diagnosed glioblastoma in radiotherapy and chemotherapy, used for postoperative synchronous radiochemotherapy for newly diagnosed glioblastoma, and taken at the same time as chemotherapy.
[0015] The pharmaceutical composition includes: a combination of two separate reagents, temozolomide (TMZ for short) and apatinib mesylate, wherein the ratio of apatinib mesylate to temozolomide is 1:1.25, and in each pharmaceutical composition The content of apatinib mesylate is 250mg.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com